AIM:OBD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United Kingdom and Malaysia. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Oxford BioDynamics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OBD is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: OBD's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-4.8%

OBD

-3.8%

GB Life Sciences

-1.7%

GB Market


1 Year Return

-31.2%

OBD

14.9%

GB Life Sciences

-8.7%

GB Market

Return vs Industry: OBD underperformed the UK Life Sciences industry which returned 14.9% over the past year.

Return vs Market: OBD underperformed the UK Market which returned -8.7% over the past year.


Shareholder returns

OBDIndustryMarket
7 Day-4.8%-3.8%-1.7%
30 Day6.1%5.6%3.7%
90 Day-18.2%28.1%14.8%
1 Year-31.2%-31.2%15.6%14.9%-4.9%-8.7%
3 Year-57.8%-57.8%12.2%10.6%3.7%-9.0%
5 Yearn/a67.8%64.9%47.0%13.7%

Long-Term Price Volatility Vs. Market

How volatile is Oxford BioDynamics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oxford BioDynamics undervalued compared to its fair value and its price relative to the market?

4.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OBD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OBD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OBD is unprofitable, so we can't compare its PE Ratio to the GB Life Sciences industry average.

PE vs Market: OBD is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OBD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OBD's PB Ratio (4.7x) is in line with the GB Life Sciences industry average.


Next Steps

Future Growth

How is Oxford BioDynamics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oxford BioDynamics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Oxford BioDynamics performed over the past 5 years?

-12.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OBD is currently unprofitable.

Growing Profit Margin: OBD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OBD is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare OBD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OBD is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (31.5%).


Return on Equity

High ROE: OBD has a negative Return on Equity (-22.62%), as it is currently unprofitable.


Next Steps

Financial Health

How is Oxford BioDynamics's financial position?


Financial Position Analysis

Short Term Liabilities: OBD's short term assets (£15.2M) exceed its short term liabilities (£1.3M).

Long Term Liabilities: OBD's short term assets (£15.2M) exceed its long term liabilities (£625.0K).


Debt to Equity History and Analysis

Debt Level: OBD is debt free.

Reducing Debt: OBD has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if OBD has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OBD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Oxford BioDynamics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OBD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OBD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OBD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OBD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OBD's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Jon Anthony Burrows (57 yo)

0.83

Tenure

Dr. Jon Burrows, PhD, serves as the Chief Executive Officer at Oxford BioDynamics Plc since March 23, 2020. He has been President of Contract Services and Senior Vice President of Corporate Development at ...


Leadership Team

NamePositionTenureCompensationOwnership
Paul Stockdale
CFO & Director3.33yrsUK£183.00k0.016%
£ 11.8k
Alexandre Akoulitchev
Chief Scientific Officer & Director13.58yrsUK£220.00k6.65%
£ 4.8m
Jon Anthony Burrows
Chief Executive Officer0.83yrno datano data
Aroul Ramadass
Chief Technology Officer4.25yrsno data6.3%
£ 4.6m
Ewan Hunter
Group CDO1.58yrsno datano data
Martin Reeves
Senior Vice President of Commercial Development3.83yrsno datano data
Glen Ferguson
Group CBO1yrno datano data
Bartu Ahiska
Senior Vice President of Commercial1.58yrsno datano data
Bipin Patel
Head of RA/QA1yrno datano data
Susan Steven
Company Secretaryno datano datano data
Steven Tucker
Group Clinical Directorno datano datano data
Siamon Gordon
Clinical Director of Inflammation & Infectionno datano datano data

1.6yrs

Average Tenure

57yo

Average Age

Experienced Management: OBD's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Stockdale
CFO & Director3.33yrsUK£183.00k0.016%
£ 11.8k
Alexandre Akoulitchev
Chief Scientific Officer & Director13.58yrsUK£220.00k6.65%
£ 4.8m
David M. Holbrook
Independent Non-Executive Director1.75yrsUK£15.00kno data
Edward Sikora
Member of Scientific Advisory Boardno datano datano data
Stephen Diggle
Non-Executive Director4.25yrsUK£1.000.47%
£ 340.4k
Iain McInnes
Member of Scientific Advisory Board1.25yrsno datano data
Jane Mellor
Member of Scientific Advisory Boardno datano datano data
Ooi Peng-Jin
Member of Scientific Advisory Boardno datano datano data
Matthew Wakefield
Non-Executive Chairman0.083yrno datano data

2.5yrs

Average Tenure

59yo

Average Age

Experienced Board: OBD's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oxford BioDynamics Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oxford BioDynamics Plc
  • Ticker: OBD
  • Exchange: AIM
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£72.891m
  • Shares outstanding: 92.56m
  • Website: https://www.oxfordbiodynamics.com

Number of Employees


Location

  • Oxford BioDynamics Plc
  • 26 Beaumont Street
  • Oxford
  • Oxfordshire
  • OX1 2NP
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OBDAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2016
OXBO.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2016

Biography

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United Kingdom and Malaysia. The company pro...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 20:21
End of Day Share Price2021/01/15 00:00
Earnings2020/03/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.